CBA-1535 is under clinical development by Chiome Bioscience and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CBA-1535’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBA-1535 overview
CBA-1535 (TB-535H) is under development for the treatment of advanced solid tumors like small cell lung cancer, non- small cell lung cancer pleural malignant mesothelioma and triple negative breast cancer. It was also under development for the treatment of KRAS mutated colorectal cancer. It targets CD3 and trophoblast glycoprotein. It is a T-cell engager tri-specific antibody developed based on tribody technology.
Chiome Bioscience overview
Chiome Bioscience operates as a healthcare service company that provides research and development of therapies. The company research and develops antibody drugs for the treatment of autoimmune and inflammatory diseases. Its ADLib system is a monoclonal antibody generating system provides various arrays of antibodies in vitro, without using immunization. Chiome Bioscience uses the ADLib system to generate therapeutic antibodies, prepares antibodies against antigens and licenses them out to pharmaceutical manufacturers and licenses the ADLib system and others. The company discovers monoconal antibody through ADLib system. It caters drug discovery companies, drug manufacturers and biotech companies to develop antibody drugs through programs. The company operates through its laboratory located in Kanagawa, Japan. Chiome Bioscience is headquartered in Tokyo, Japan.
For a complete picture of CBA-1535’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
